A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Prior treatment

• Previous treatment of CML with any other anticancer agents including chemotherapy and/or biologic agents or prior stem cell transplant, with the exception of hydroxyurea and/or anagrelide. Treatment with either imatinib, or nilotinib, or dasatinib or bosutinib for ≤2 weeks is allowed, but no other treatment with other tyrosine kinase inhibitors prior to randomization is permitted.
• Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection; uncontrolled arterial or pulmonary hypertension, uncontrolled clinically significant hyperlipidemia). Please refer to Section 6.3.1
• Major surgery within 4 weeks prior to study entry or who have not recovered from prior surgery.
• History of other active malignancy within 3 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively
• History of acute pancreatitis within 1 year prior to randomization or medical history of chronic pancreatitis.
• Severe and/or uncontrolled concurrent medical disease that in the opinion of the Investigator could cause unacceptable safety risks or compromise compliance with the protocol

Other illness

• History of significant congenital or acquired bleeding disorder unrelated to cancer.
• History of chronic liver disease leading to severe hepatic impairment, or ongoing acute liver disease.
• Known hypersensitivity to the study treatment
  • Other protocol-defined Inclusion/exclusion criteria will apply.
• Impaired cardiac function or cardiac repolarization abnormality

Lab values

• Impaired cardiac function or cardiac repolarization abnormality including but not limited to any one of the following:
  • History within 6 months prior to starting study treatment of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG)
  • Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block)
  • QTc ≥ 450 ms (male patients), ≥460 ms (female patients) on the average of three serial baseline ECG (using the QTcF formula) as determined by central reading. If QTcF ≥ 450 ms and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc.
  • Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
  • Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia
  • Concomitant medication(s) with a "Known risk of Torsades de Pointes" per www.crediblemeds.org/ that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.•Inability to determine the QTcF interval

Other

• Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required).
• Participants meeting the following additional criterion are not eligible for the inclusion in the optional TFR Period:
• Participants in the treatment re-initiation (TRI) Period cannot re-enter TFR for a second TFR attempt
• Participants meeting the following additional criterion are not eligible to enter the TRI Period:
• In case of a pregnancy during the TFR Period, the pregnant woman must be discontinued upon loss of MMR (\>0.1% BCR::ABL1 IS at a single assessment) and cannot enter the TRI Period

• Participants eligible for inclusion in this study must meet all of the following criteria:
• Male or female patients ≥ 18 years of age.
• Participants with CML-CP within 3 months of diagnosis.
• Diagnosis of CML-CP (ELN 2020 criteria) with cytogenetic confirmation of Philadelphia chromosome
  • Documented chronic phase CML will meet all the below criteria (Hochhaus et al 2020):
• \< 15% blasts in peripheral blood and bone marrow,
• \< 30% blasts plus promyelocytes in peripheral blood and bone marrow,
• \< 20% basophils in the peripheral blood,
• Platelet count ≥ 100 x 10\^9/L (≥ 100,000/mm\^3),
• No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate end organ function as defined by:
• Total bilirubin \< 3 x ULN; patients with Gilbert's syndrome may only be included if total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN
• Creatinine clearance (CrCl) ≥ 30 mL/min as calculated using Cockcroft-Gault formula,
• Serum lipase ≤ 1.5 x ULN. For serum lipase \> ULN - ≤ 1.5 x ULN, value must be considered not clinically significant and not associated with risk factors for acute pancreatitis
  • \- Participants must have the following laboratory values within normal limits or corrected to within normal limits with supplements prior to randomization:
• Potassium (potassium increase of up to 6.0 mmol/L is acceptable if associated with CrCl\* ≥ 90 mL/min)
• Total calcium (corrected for serum albumin); (calcium increase of up to 12.5 mg/dl or 3.1 mmol/L is acceptable if associated with CrCl\* ≥ 90 mL/min)
• Magnesium (magnesium increase of up to 3.0 mg/dL or 1.23 mmol/L if associated with CrCl\* ≥ 90 mL/min)
• For patients with mild to moderate renal impairment (CrCl\* ≥ 30 mL/min and \<90 mL/min) - potassium, total calcium (corrected for serum albumin) and magnesium should be ≥ LLN or corrected to within normal limits with supplements prior to randomization.
• \*CrCl as calculated using Cockcroft-Gault formula
  • Ability to provide written informed consent prior to any study related screening procedures being performed.
  • Evidence of typical BCR-ABL1 transcript \[e14a2 and/or e13a2\] at the time of screening which is amenable to standardized Real time quantitative polymerase chain reaction (RQ-PCR) quantification.
• Participants meeting the following additional criteria are not eligible to enter the TRI Period:
• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures
• A minimum of 5 years of study treatment up to maximum of 6 years of study treatment (i.e. participants are eligible to enter TFR any time between year 5 and year 6 of their study treatment
• Sustained MR 4.0 (BCR::ABL1 IS ≤0.01%) or better, assessed by central laboratory for at least 2 years (equivalent to 104 weeks) which includes MR 4.5 (BCR::ABL1 IS ≤0.0032%) for at least 1 year (equivalent to 52 weeks) immediately prior to entry into the TFR Period, with the 5 last consecutive RQ-PCR (every 12 weeks) assessments at/or below MR 4.5. Entry into TFR Period should be no later than 12 weeks from the last MR 4.5 RQ-PCR assessment
• Separate signed informed consent must be obtained prior to participation in the TFR Period